Page last updated: 2024-09-05

sb 203580 and sb 225002

sb 203580 has been researched along with sb 225002 in 1 studies

Compound Research Comparison

Studies
(sb 203580)
Trials
(sb 203580)
Recent Studies (post-2010)
(sb 203580)
Studies
(sb 225002)
Trials
(sb 225002)
Recent Studies (post-2010) (sb 225002)
3,48941,13792073

Protein Interaction Comparison

ProteinTaxonomysb 203580 (IC50)sb 225002 (IC50)
C-X-C chemokine receptor type 1Homo sapiens (human)0.022
C-X-C chemokine receptor type 2Homo sapiens (human)0.0623

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cui, D; Xu, J; Zhao, Y1

Other Studies

1 other study(ies) available for sb 203580 and sb 225002

ArticleYear
Activation of CXCL5-CXCR2 axis promotes proliferation and accelerates G1 to S phase transition of papillary thyroid carcinoma cells and activates JNK and p38 pathways.
    Cancer biology & therapy, 2019, Volume: 20, Issue:5

    Topics: Animals; Anthracenes; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL5; G1 Phase Cell Cycle Checkpoints; Humans; Imidazoles; MAP Kinase Signaling System; Mice; Mice, Nude; Phenylurea Compounds; Phosphorylation; Pyridines; Receptors, Interleukin-8B; Recombinant Proteins; Thyroid Cancer, Papillary; Thyroid Neoplasms; Xenograft Model Antitumor Assays

2019